Matthew Caulfield
Analyst
H.C. Wainwright
Equibles does not estimate personal net worth.
About Matthew Caulfield
Matthew Caulfield is recorded as Analyst at H.C. Wainwright. Matthew Caulfield has spoken on 11 earnings calls and 3 other investor events across 8 companies, most recently for Phathom Pharmaceuticals, Inc. on September 15, 2026. Those appearances were for DiaMedica Therapeutics Inc. (DMAC), Mineralys Therapeutics, Inc. (MLYS), Tarsus Pharmaceuticals, Inc. (TARS), Ardelyx, Inc. (ARDX), Akebia Therapeutics, Inc. (AKBA) and 3 other companies. The companies whose calls Matthew Caulfield spoke on are classified in the Healthcare sector.
Matthew Caulfield on recent calls
“Well, welcome back to H.C. Wainwright's 28th Annual Global Investment Conference. My name is Matthew Caulfield. I'm a Senior Biotech Analyst here at H.C. Wainwright, and we're very grateful to be joined by Fathom Pharmaceuticals.”
“For the Phase 2-3 Remedy Trial, the interim analysis looks like it's slightly shifted from fourth quarter to early 27. You've noted the 85% enrolled towards the interim analysis.”
“Very exciting and looking forward to December. Thanks again. Thanks, Matthew.”
“Really great to see the range of updates this morning. So two questions from us. With the evolving pipeline, now with data catalysts across the coming years, is there any shift to the prioritization of programs other than the partnership potential for Lyme disease?”
“Just focusing on the discussed the access challenges for Adrella appreciated the color and the comments there so far. But are there any, are these factors something that's gotten worse over the past couple quarters?”
Affiliation history
-
H.C. Wainwright
Analyst
Transcript header (unverified)
Current
Company network
ARDX
Biotechnology · Healthcare
Drug Manufacturers - Specialty & Generic · Healthcare
SRZN
Biotechnology · Healthcare